Immuno-Oncology
Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell Lymphoma
August 04, 2022
Article
Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
Rone Discusses Exciting Immunotherapy Research in Gastrointestinal Cancer
August 02, 2022
Article
Kelley A. Rone, DNP, RN, ADNP-c, highlights the pivotal trials assessing the role of immunotherapy in gastrointestinal cancer and what the findings may mean for oncology nurses.
Sandy on the Practicalities of Molecular Testing in Newly Diagnosed Lung Cancer
August 01, 2022
Article
Beth Sandy, MSN, CRNP, discusses some of the challenges that may be associated with molecular testing, and how oncology nurses can help play a role in ensuring that the reports are received.
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
July 28, 2022
Video
Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical Implementation
July 27, 2022
Article
In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
Tremelimumab Plus Durvalumab Bests Sorafenib OS Rates In Frontline HCC Treatment
July 17, 2022
Article
Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
July 13, 2022
Article
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
Adding Durvalumab to Chemotherapy Continues to Improve Overall Survival in Advanced Biliary Tract Cancer
July 11, 2022
Article
A subgroup analysis found that the addition of durvalumab to chemotherapy resulted in maintained overall survival benefit in patients with advanced biliary tract cancer, regardless of primary tumor location.
Expanded Safety Analysis from CheckMate 648 Shows Tolerability with Frontline Nivolumab Combinations in ESCC
June 29, 2022
Article
Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.
FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma
June 24, 2022
Article
The FDA has approved lisocabtagene maraleucel as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma.